| dc.contributor.author | Gerlinger, M | |
| dc.date.accessioned | 2021-04-12T08:47:34Z | |
| dc.date.available | 2021-04-12T08:47:34Z | |
| dc.date.issued | 2021-01-11 | |
| dc.identifier.citation | Cancer cell, 2021, 39 (1), pp. 16 - 18 | |
| dc.identifier.issn | 1535-6108 | |
| dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/4515 | |
| dc.identifier.eissn | 1878-3686 | |
| dc.identifier.doi | 10.1016/j.ccell.2020.12.016 | |
| dc.description.abstract | Abundant neoantigens are considered responsible for the immunotherapy sensitivity of mismatch repair-deficient (MMRd) cancers. In this issue of Cancer Cell, two papers show that MLH1 mismatch repair gene loss promotes cGAS-STING activation, interferon secretion, and T cell priming. This may be essential for the high immunotherapy sensitivity in MMRd cancer. | |
| dc.format | Print | |
| dc.format.extent | 16 - 18 | |
| dc.language | eng | |
| dc.language.iso | eng | |
| dc.publisher | CELL PRESS | |
| dc.rights.uri | https://www.rioxx.net/licenses/under-embargo-all-rights-reserved | |
| dc.title | Immunotherapy Sensitivity of Mismatch Repair-Deficient Cancer: Mutation Load Is Not Enough. | |
| dc.type | Journal Article | |
| dcterms.dateAccepted | 2020-12-07 | |
| rioxxterms.version | AM | |
| rioxxterms.versionofrecord | 10.1016/j.ccell.2020.12.016 | |
| rioxxterms.licenseref.uri | https://www.rioxx.net/licenses/under-embargo-all-rights-reserved | |
| rioxxterms.type | Journal Article/Review | |
| dc.relation.isPartOf | Cancer cell | |
| pubs.issue | 1 | |
| pubs.notes | Not known | |
| pubs.organisational-group | /ICR | |
| pubs.organisational-group | /ICR/Primary Group | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Translational Oncogenomics | |
| pubs.organisational-group | /ICR | |
| pubs.organisational-group | /ICR/Primary Group | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Translational Oncogenomics | |
| pubs.publication-status | Published | |
| pubs.volume | 39 | |
| pubs.embargo.terms | Not known | |
| icr.researchteam | Translational Oncogenomics | |
| icr.researchteam | Translational Oncogenomics | |
| dc.contributor.icrauthor | Gerlinger, Marco | |
